fda glp-1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Managing Compounded GLP-1 Medications: A

Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) , in StatPearls

The oral formulation is the most significant differentiator: if an oral tablet can produce weight loss comparable to injectable CagriSema, it could fundamentally change how dual pathway obesity therapy is delivered

While it doesn't predict exact weight loss speed, it reveals your predisposition toward GLP-1 sensitivity and helps your provider optimize medication choice and dosing strategy

For people who were on statins before starting semaglutide, the combined effect of the statin and semaglutide-mediated fat loss can sometimes move lipid markers significantly